• 1
    Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, McCrum WR. Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Ann Intern Med 1974; 80: 216.
  • 2
    The Cooperating Clinics Committee of the American Rheumatism Association. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973; 16: 3538.
  • 3
    Jeurissen ME, Boerbooms AM, van de Putte LB, Doesburg WH, Lemmens AM. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. Ann Intern Med 1991; 114: 9991004.
  • 4
    Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993; 36: 6139.
  • 5
    Van der Heijde DM, van Riel PL, Nuvar-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 10368.
  • 6
    Førre Ø, and the Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994; 37: 150612.
  • 7
    Empire Rheumatism Council Subcommittee. Empire Rheumatism Council multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in long-term treatment of rheumatoid arthritis: results of three years' treatment. Ann Rheum Dis 1957; 16: 27788.
  • 8
    Joint Committee of the Medical Research Council and Nuffield Foundation. Joint Committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH and other therapeutic measures in chronic rheumatic disease: a comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1959; 18: 17386.
  • 9
    Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595603.
  • 10
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon GW, et al, on behalf of the Leflunomide RA Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch Intern Med 1999; 159: 254250.
  • 11
    United States Food and Drug Administration. Guidance document for clinical development programs for drugs, devices, and biologics for the treatment of rheumatoid arthritis. Washington (DC): FDA; 1999.
  • 12
    Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 70620.
  • 13
    Sharp JT, Bluhm GB, Brook A, Brower AC, Corbett M, Decker JL, et al. Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 1985; 28: 1624.
  • 14
    Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985; 28: 132635.
  • 15
    Sharp JT, Wolfe F, Mitchell DM, Bloch DA. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 1991; 34: 6608.
  • 16
    Larsen A. A radiologic method for grading the severity of rheumatoid arthritis. Scand J Rheumatol 1975; 4: 22533.
  • 17
    Larsen A, Edgren J, Harju E, Laasonen L, Reitamo T. Inter-observer variation in the evaluation of radiologic changes of rheumatoid arthritis. Scand J Rheumatol 1979; 8: 10912.
  • 18
    Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 1995; 10: 19745.
  • 19
    OMERACT IV. Outcome measures in rheumatology: Cancun, Mexico, April 16-20, 1998. J Rheumatol 1999; 26: 459507.
  • 20
    Boers M, Tugwell P, Felson DT, van Riel PLCM, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994; 21 Suppl 41: 869.
  • 21
    Leung H, Hurley F, Strand V. Workshop: issues involved in a meta-analysis of RA radiographic progression—analysis issues. J Rheumatol. In press.
  • 22
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 23
    Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-l receptor antagonist. Arthritis Rheum 1998; 41: 2196204.
  • 24
    Rich E, Moreland LW, Alarcón GS. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as first disease modifying drug. J Rheumatol 1999; 26: 25961.
  • 25
    Maravic M, Bologna C, Daures JP, Jorgensen C, Combe B, Sany J. Radiographic progression in early rheumatoid arthritis treated with methotrexate. J Rheumatol 1999; 26: 2627.
  • 26
    Paulus H, Sharp JT. J Rheumatol. In press.
  • 27
    Kirwan J, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 1426.
  • 28
    Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 30918.
  • 29
    Amos RS, Constable TJ, Crockson RA, Crockson AP, McConkey B. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. BMJ 1977; 1: 1957.
  • 30
    Eberhardt KB, Truedsson L, Pettersson H, Svensson B, Stigsson L, Eberhardt JL, et al. Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor. Ann Rheum Dis 1990; 49: 9069.
  • 31
    Stockman A, Emery P, Doyle T, Hopper J, Tait B, Muirden K. Relationship of progression of radiographic changes in hands and wrists, clinical features and HLA-DR antigens in rheumatoid arthritis. J Rheumatol 1991; 18: 100017.
  • 32
    Van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts and acute phase reactants. J Rheumatol 1994; 21: 4259.
  • 33
    Wollheim FA, Pettersson H, Saxne T, Sjoblom KG. Radiographic assessment in relation to clinical and biochemical variables in rheumatoid arthritis. Scand J Rheumatol 1988; 17: 44553.
  • 34
    Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998; 41: 157182.